key: cord-0788610-p4ettcgi authors: Tantuoyir, Marcarious M.; Rezaei, Nima title: Serological Tests for COVID‐19: Potential Opportunities date: 2020-12-02 journal: Cell Biol Int DOI: 10.1002/cbin.11516 sha: 8c477d4b9ca48bdd4f5b3730eff44da5638963f0 doc_id: 788610 cord_uid: p4ettcgi Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is a novel betacoronavirus, caused a pandemic leading to a standstill of nearly all global activities. There are some controversies on the production of specific IgM and IgG antibodies after the infection with SARS‐CoV‐2. This paper seeks to elaborate on the potential application of IgM and IgG antibodies and the viral antigens for the diagnosis and the course of the disease as well as the recurrence of positive nucleic acid tests after discharge. This article is protected by copyright. All rights reserved. In December 2019, the world was hit a novel virus, known as SARS-CoV-2, which later developed in a pandemic causing the coronavirus disease . It has since then infected over 30 million people all over the world with over 24 million recoveries and over about a million deaths (end of September 2020). Real-time reverse-transcriptase polymerase chain reaction (rRT-PCR) continues to be a test technique that is widely used to validate the results of both symptomatic and asymptomatic patients of COVID-19. Though there have been improvements in this technique, parts of the world like the United States still have a limited track record of rRT-PCR testing. In other places like China, this method was used for clinical COVID-19 patients and it produced suboptimal sensitivity results with 72 out of 104 sputa being positive, 5 out of 8 nasal swabs, and 126 out of 392 pharyngeal swabs being positive. These results conform with barriers that have This article is protected by copyright. All rights reserved. already been seen in the molecular diagnosis of this novel coronavirus, SARS-CoV-2. Some of these challenges include but not limited to low viral count during the onset of the disease, lack of a gold standard to confirm various tests and also, the wide genetical variations in the strains that have been identified. To augment the rRT-PCR technique, some serological tests of various forms were created that can probe immunoglobulins like IgG and IgM for viral proteins of SARS-CoV-2. However, just like the rRT-PCR, these tests also have their barriers. So far, the challenges that have been seen across different regions include delayed positivity, response and function of the host immune system, and interference of other coronaviruses in detecting SARS-CoV-2. (Ozturk et al., 2020) The human immune system produces antibodies which are mainly blood proteins that serve a function of protecting the body from the attack of both external and internal substances or organisms that are recognized as foreign to the body like viruses. These antibodies can avert future attacks from similar or the same foreign bodies and are mainly found in the bloodstream and body secretions, such as saliva. The immune systems' response to SARS-CoV-2 through the antibodies produced against it is important to determine the progress of the disease and also in providing the best available supportive care. (Saghazadeh & Rezaei, 2020b) Antibodies like IgG and neutralizing antibodies are specific for their function and therefore are very important for preventing an individual's immune system from attack and averting pathogens into the cells after a viral attack leading to an infection. The antibody detection gives vital clinical information of a viral attack just like in COVID-19 patients. A study reports that researchers at Chongqing Medical University found out that almost all This article is protected by copyright. All rights reserved. 285 COVID-19 patients in their study produced immunoglobulin M (IgM), as it is the foremost antibody that is produced during an infection to protect the body. Only 40% of the patients produced IgM in their first week when they got infected with the SARS-CoV-2 but this percentage of patients saw a drastic rise to about 95% in the following two weeks i.e 12 to 14 days. All the subjects in this study also produce IgG antibodies. So far, the antibodies that are most important in SARS-CoV-2 are the IgG antibodies. Antibodies to SARS-CoV-2 can be found in the middle and later stages of the disease. Antibody detection can play an important role in the COVID-19 diagnosis as a complementary approach to assays with viral nucleic acids. (Nasab et al., 2020) Antibody tests of the blood (and in some cases saliva) detect whether the antibody is present or absent. Although their production in COVID-19 patients occurs later as compared to IgM, IgGs have the noumenon to confer sustained immunity to COVID-19 patients. (Jahanshahlu & Rezaei, 2020) Using evidence from other coronaviruses such as human endemic coronaviruses (HCoVs), SARS-CoV-1 and MERS-CoV can provide clues and guide future prediction and research on sustained immunity on SARS-CoV-2. Table 1 looks at the main antibodies involve in SARS-CoV-2 disease clinical response. (Iyer et al., 2020; Peeling et al., 2020; Ravi et al., 2020) against N protein which can be detected by serum as early as day 4 after the onset of disease and with most patients being seroconverted by day 14 (Rokni et al., 2020) but studies using an antigen S are more sensitive than tests based on antigen N with IgG tests performing better than IgM tests. After symptom onset, N and S specific IgM and IgG steadily increases and can be used for identification of SARS-CoV-2 infection. S-IgG dynamics analysis can aid in predicting prognosis. Increase in S-IgG positively associated with decrease in C-reactive protein (CRP). It has been recognized that S-specific antibodies can block the binding of S protein to the cellular hACE2 receptor, which mediates the binding and entry of SARS-CoV-2 into target cells. There is no evidence that the N-specific antibodies could prevent infection with the virus. Due to its high immunogenicity and intracellular aggregation before virus packaging, N protein is a suitable candidate for early diagnosis of infection. Therefore, a continuous rise in N-IgG can indicate progression of disease towards more serious disease. SARS-CoV and MERS-CoV studies have shown that various fragments (S1-NTD, RBD, S2) in S proteins can be used as targets for the production of nAbs. RBD-based antibodies have greater potential to neutralize diver-gentle virus strain infection, indicating that SARS-CoV-2 RBD may also serve as a significant target for the production of potent and sensitive nAbs. Table 2 gives an overview of the structural viral proteins (antigens) associated with SARS-COV-2. Tethers the viral genome to replicase-transcriptase complex, packages the encapsulated genome into viral particles A transmembrane protein with ion channel activity Facilitates assembly and release of the virus; involved in ion channel activity Binds to nucleocapsid Promotes membrane curvature Binds sialic acids on surface glycoproteins Thought to enhance S protein-mediated cell entry and virus spread through mucosa Serological testing is traditionally defined as a diagnostic technique used to determine an immune response to an infectious agent. (Lippi et al., 2020) This article is protected by copyright. All rights reserved. variation in the positive diagnosis of these two antibodies. It was observed that a rise in IgM values seems to cut across both critical and severe cases but the IgG number was lower specifically for critically ill patients than the other groups of cases. It is speculated that these results may be due to a weakened immune reaction or a strong results of study subjects with COVID-19 pneumonia. (Mózo, 2017) Young individuals infected with SARS-CoV-2 are seen not to be presenting classical symptoms with a fast-viral clearance and decreased IgM with an increased total antibodies, IgG and IgA. Xiao et al., (2020) suggest that their study results give a strong basis for viral clearance and antibody kinetics of patients without classical symptoms of COVID-19. Table 3 summarizes some of the major serological tests, comparing them on various parameters. This article is protected by copyright. All rights reserved. COVID-19 has evolved swiftly from just a cluster of pneumonia-like cases to a pandemic which is still spreading daily. In both clinical and research findings, it has been seen that the serological tests for antibodies are very significant especially when combined with RNA tests like rRT-PCR. There are several drawbacks to the real-time PCR test kits. Initial studies indicated that they recorded high false-negative rates. RT-PCR used for pharyngeal swaps gave different results which shows that they are (single or combined) is the best option in these different contexts. Table 4 summarizes diagnostic considerations between rt-PCR and serological assays. High-level selection of IgG antibodies could be helpful in the production of vaccines and in the treatment of SARS-CoV-2 by convalescent plasma therapy. (Infantino et al., 2020) In the future, this detailed collation of the latest immunoassays against SARS-CoV-2 will provide insights into the detection and characterization of monoclonal antibodies for developing a SARS-CoV-2 vaccine.(C. Y.-P. Immunity to COVID-19 Humoral immune response, in particular the production of neutralizing antibody, infection. It is seen that patients that are positively responding to treatment and have re-detectable viral RNA showed lesser IgG amounts proposing that, the reduction in the amount of IgG as the patient recovers gives a hint that a sustained immunity from IgG is not likely and this should be thoroughly assessed to ascertain a conclusive result since pertinent issues concerning herd immunity against SARS-CoV-2 relies on the ability of IgG to confer sustained and life-long immunity to people previously infected by the virus. (Randolph & Barreiro, 2020) This article is protected by copyright. All rights reserved. in the course of infection allowed the detection of SARS-CoV-2-specific antibodies and were only reliably positive longer than 4 weeks after the onset of the disease. Suggesting that, the use of serology for acute disease diagnosis must be treated with caution and real time RT-PCR for virus detection remains the method of choice. (Bastos et al., 2020; Perera et al., 2020) Overall, re-searching on SARS-CoV-and MERS-CoV-specific nAbs should therefore provide valuable guidance for the rapid design and production of SARS-CoV-2-specific nAbs. So far, the development of serological tests targeting a wide This article is protected by copyright. All rights reserved. range of viral antigens has certainly helped to diagnose COVID-19 patients accurately. Contact tracing, viral reservoir recognition, and epidemiological studies are some aspects of COVID-19 validated by serological assays. These are assays will be instrumental in tracking patient contacts, serosurveillance studies and assessment of vaccines. (Okba et al., 2020) Antibodies detection, thus IgM and IgG, in COVID-19 patients is a rapid and easy technique. Using the serological method of detecting SARS-CoV-2 in addition to RNA testing is very important in our quest to unravel the course of disease progression in COVID-19 patients, right from the onset to end of disease in an individual. The serological test for IgG and IgM antibodies is a technique that can be relied on since this method proves to be accurate and also sensitive in detecting the virus. (Krüttgen et al., 2020; Pan et al., 2020) However, it is recommended that this technique should be performed together with rRT-PCR or RNA test to give more certainty to the results in terms of sensitivity and accuracy. This approach will give room for rapid diagnosis and timely intervention to COVID-19 patients and suspected carriers from contact tracing especially when they are tested negative using the rRT-PCR method. Moving forward, there is an urgent need for medical research to determine and ascertain the number of antibodies against SARS-CoV-2 for the prediction of the outcome of COVID-19, as suggested by Du et al., (2020) Yazdanpanah et al., 2020) knowing that there exists a rather complex relationship in the number of antibodies, the prognosis of COVID-19, and the start of symptoms. There is also the need to probe into ways of detecting the antibody levels of a patient which can aid in correct forecasting of disease progress and severity in a Accepted Article patient if it is ascertained accurately at the start of the disease. (Fathi & Rezaei, 2020) S-IgG developed steadily in severe cases. It was significantly lower in severe patients by 2 weeks after the onset than non-severe patients, which may explain the longer hospital stays and positive days of nucleic acid in severe patients. Therefore, tracking S-IgG's kinetics can help predict prognosis. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Clinical Characteristics of Re-hospitalized Patients with COVID-19 in China Detection of antibodies against SARS-CoV-2 in patients with COVID-19 Review of Current Advances in Serologic Testing for COVID-19 Lymphopenia in COVID-19: Therapeutic opportunities Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2 Detection of IgM and IgG antibodies in patients with coronavirus disease Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19 Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients Monoclonal antibody as a potential anti-COVID Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019 Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays Antibody tests in detecting SARS-CoV-2 infection: A meta-analysis Comparison of four new commercial serologic assays for determination of SARS-CoV-2 IgG Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control Dynamics of anti-SARS-Cov-2 IgM and IgG antibodies among COVID-19 patients Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19 Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis Current laboratory diagnostics of coronavirus disease 2019 (COVID-19) A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections COVID-19: Transmission, prevention, and potential therapeutic opportunities SARS-CoV-2: A comprehensive review from pathogenicity of the virus to clinical consequences Elevated serum IgM levels indicate poor outcome in patients with coronavirus disease 2019 pneumonia: A retrospective case-control study SARS-CoV-2-A Tough Opponent for the Immune System Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients Cross-sectional IgM and IgG profiles in SARS-CoV-2 infection IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients Serology testing in the COVID-19 pandemic response. The Lancet Infectious Diseases Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Profile of Immunoglobulin G and IgM Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Herd Immunity: Understanding COVID-19. This article is protected by copyright. All rights reserved Diagnostics for SARS-CoV-2 detection: A comprehensive review of the FDA-EUA COVID-19 testing landscape Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids Immune-epidemiological parameters of the novel coronavirus -a perspective Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerging Microbes and Infections Laboratory Diagnosis of COVID-19: Current Issues and Challenges The role of antibody testing for sars-cov-2: Is there one? Early viral clearance and antibody kinetics of COVID-19 among asymptomatic carriers Characteristics of Patients with Coronavirus Disease Confirmed using an IgM-IgG Antibody Test The immune system and COVID-19: Friend or foe? Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease Early detection of SARS-CoV-2 antibodies in COVID-19 patients as a serologic marker of infection Funding: None The authors declare that they have no conflicts of interest.